Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Life Technologies Showcases Leading Technologies For Cancer Research At AACR

Life Technologies Corp. (LIFE: Quote) said it will exhibit products across the spectrum of basic, translational and clinical cancer research during the American Association of Cancer Research or AACR Annual Meeting 2012, taking place March 31 - April 4, in Chicago, Illinois.

Presentations included in this exhibition are triple negative breast cancer, Semiconductor sequencing of melanoma samples, the company said.

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin. To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010; early results will be presented by John Carpten, head of the Integrated Cancer Genomics Division at the Phoenix-based Translational Genomics Research Institute or Tgen.

In addition, George Watts, research assistant professor and co-director of the Genomics Shared Service at The University of Arizona Cancer Center, will present a poster demonstrating accurate, cost-effective sequencing of six commonly mutated genes in archived research samples from metastatic melanoma patients using the Life Technologies Ion Personal Genome Machine system.

Register
To receive FREE breaking news email alerts for Life Technologies Corporation and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Micro-blogging site Twitter Inc said Tuesday after the markets closed that its second quarter loss widened from last year, hurt mainly by stock-based compensation expense, even as revenue more than doubled thanks to growth in advertising. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. Pharmaceutical giant Pfizer, Inc., which was aspiring to buy British drug maker AstraZeneca Plc, reported Tuesday a profit for the second quarter that plunged 79 percent from last year, which reflected hefty gains from animal health business sales. Total revenues declined 2 percent, as it continued to be hurt by generic competition for major drugs. Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.